David Shaw’s Celldex Therapeutics CLDX Stock Holding History

David Shaw’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7,107	Closed	-$1.95M	–	3668
2014 Q4	$1.95M	Sell	7,107 -6,666	-48%	-$1.66M	﹤0.01%	2307
2014 Q3	$2.68M	Buy	13,773 +3,826	+38%	+$834K	﹤0.01%	2009
2014 Q2	$2.44M	Buy	9,947 +2,840	+40%	+$641K	﹤0.01%	2155
2014 Q1	$1.88M	Sell	7,107 -1,666	-19%	-$638K	﹤0.01%	2450
2013 Q4	$3.19M	Buy	8,773 +1,160	+15%	+$447K	﹤0.01%	2073
2013 Q3	$4.05M	Buy	7,613 +4,946	+185%	+$1.7M	0.01%	1794
2013 Q2	$624K	Buy	+2,667	New	+$525K	﹤0.01%	3083

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's CLDX Position: Q2 2026 in Review

David Shaw reduced its Celldex Therapeutics (CLDX) stake by 66% in Q2 2026, selling an estimated $1.13M and leaving 17,826 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

David Shaw first reported a position in CLDX in Q2 2013 and has held it in 45 quarters since. The position peaked at $31.3M in Q2 2024. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

David Shaw held 17,826 shares of Celldex Therapeutics worth $663K as of Q2 2026.
David Shaw sold 35,034 Celldex Therapeutics shares in Q2 2026, an estimated $1.13M.
Celldex Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4028 holding.
David Shaw first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 45 quarters since.
David Shaw's Celldex Therapeutics position peaked at $31.3M in Q2 2024.
252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.